CSF3R and Decreased total neutrophil count: Concurrently, BTK inhibition impairs G-CSF receptor signaling (reduced STAT5 phosphorylation) while enhancing CXCR4-mediated marrow retention, explaining why plerixafor outperforms G-CSF monotherapy in mitigating neutropenia [34].